This Week at the Food & Drug Administration — week of June 1, 2026

The Food and Drug Administration took 11 actions this week, and nearly all followed the same pattern: classifying newly recognized medical devices into Class II, the moderate-risk tier. That classification matters because it lets manufacturers bring products to market through a standard notification process rather than a lengthy pre-approval application, while still requiring special safety controls. None of these moves approve a specific product for sale; they set the regulatory category that future devices of each type will follow. The one remaining action was a clerical fix to earlier rules for three animal drugs.

Implants and bone repair devices

• Bone void filler with antibiotic: The FDA classified CERAMENT G, a resorbable calcium salt bone filler that contains an approved antibacterial, into Class II. It fills bone gaps in the extremities where infection risk is higher.
• Ceramic shoulder implants: A device with a ceramic head and metal stem, used with or without bone cement, was placed in Class II. The change lowers compliance costs for manufacturers and signals the agency considers the technology well understood.
• Absorbable metallic bone screws: These “absorbable metallic bone fixation fasteners” dissolve in the body over time. The Class II designation requires testing and labeling but avoids the more burdensome Class III review.

Devices for pain and anesthesia

• Ultrasound for nerve blocks: The ScanNav Anatomy Peripheral Nerve Block device, used during regional anesthesia, was placed in Class II. It helps providers perform nerve blocks with more precision.
• Anesthesia pain measurement: A device that uses software to analyze sensor data and gauge how much pain a patient under general anesthesia feels was classified as Class II. It helps anesthesiologists adjust medication levels during surgery.
• Intraoral cooling devices: These devices, designed to manage oral pain during cancer treatments, were placed in Class II. They can now reach the market through the 510(k) pathway instead of the stricter premarket approval process.

Digestive and swallowing care

• Constipation capsule: An orally ingested capsule that treats constipation by passing naturally through the gastrointestinal tract was classified as Class II. The lower tier can speed patient access while keeping safety oversight through special controls.
• Oropharyngeal electrical stimulator: This device, which stimulates the throat area to treat swallowing disorders, was moved out of an automatic Class III designation. Future similar devices can use the simpler notification process, potentially speeding up access for patients.

Diagnostics and hospital equipment

• von Willebrand factor assay: A blood test that measures von Willebrand factor activity or size distribution in plasma to help diagnose related bleeding disorders was placed in Class II. The change reduces regulatory hurdles for manufacturers of these tests.
• Smart sterilization containers: Rigid sterilization containers with electronic sensors that track sterility in real time were classified as Class II. For hospitals, the classification confirms these containers meet federal safety standards for monitoring sterility.

Administrative fix for animal drugs

• Correction to animal drug rules: The FDA published a notice correcting formatting errors in a final rule from April 16, 2026, covering the animal drugs lincomycin, laidlomycin, and ractopamine. The fix addresses clerical mistakes in the Code of Federal Regulations instructions so the rules are legally accurate.

---

This weekly agency digest is generated from federal records (the Federal Register and Congress.gov) and summarized in plain English. It may simplify or omit detail — follow the linked official sources before relying on any item. Part of The Boring Parts.